CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity.

@article{Chen2001CV706AP,
  title={CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity.},
  author={Yongmei Chen and Theodore DeWeese and Jeanette Dilley and Yi Zhang and Yong Li and N. Ramesh and Jaehoon Lee and Rukmini Pennathur-Das and John Radzyminski and Joseph Wypych and Dominic Brignetti and Sara E. Scott and Jennifer Stephens and David Karpf and Daniel R. Henderson and David C. Yu},
  journal={Cancer research},
  year={2001},
  volume={61 14},
  pages={5453-60}
}
Radiation is an effective means of treating localized prostate cancer. However, up to 40% of men with certain risk factors will develop biochemical failure 5 years after radiotherapy. CV706, a prostate cell-specific adenovirus variant, is currently in clinical trials for the treatment of recurrent organ-confined prostate cancer. We demonstrated previously that a single administration of CV706 at 5 x 10(8) particles/mm3 of tumor eliminated established tumors within 6 weeks in nude mouse… CONTINUE READING